Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR‐Preserved

• Asıl Yazarlar: Andrew J.S. Coats (Yazar), Javed Butler (Yazar), Hiroyuki Tsutsui (Yazar), Wolfram Doehner (Yazar), Gerasimos Filippatos (Yazar), João Pedro Ferreira (Yazar), Michael Böhm (Yazar), Vijay K. Chopra (Yazar), Subodh Verma (Yazar), Matias Nordaby (Yazar), Tomoko Iwata (Yazar), Daisuke Nitta (Yazar), Piotr Ponikowski (Yazar), Faiez Zannad (Yazar), Milton Packer (Yazar), Stefan D. Anker (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Wiley, 2024-02-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Abstract Background Frailty is a severe, common co‐morbidity associated with heart failure (HF) with preserved ejection fraction (HFpEF). The impact of frailty on HFpEF outcomes may affect treatment choices in HFpEF. The impact of frailty on HFpEF patients and any impact on the clinical benefits of...